Carmen Gratteri

Ms. Carmen Gratteri

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAdriana Coricello
Adriana Coricello
ANAlanya J. Nardone
Alanya J. Nardone
Antonio LupiaAntonio Lupia
Antonio Lupia
CGCarmen Gratteri
Carmen Gratteri
MVMatthijn Vos
Matthijn Vos
NRNigel G. J. Richards
Nigel G. J. Richards
Advances in X-ray crystallography and cryogenic electron microscopy (cryo-EM) offer the promise of elucidating functionally relevant conformational changes that are not easily studied by other biophysical methods. Here we show that 3D variability analysis (3DVA) of the cryo-EM map for wild-type (WT) human asparagine synthetase (ASNS) identifies a functional role for the Arg-142 side chain and test this hypothesis experimentally by characterizing the R142I variant in which Arg-142 is replaced by isoleucine. Support for Arg-142 playing a role in the intramolecular translocation of ammonia between the active site of the enzyme is provided by the glutamine-dependent synthetase activity of the R142 variant relative to WT ASNS, and MD simulations provide a possible molecular mechanism for these findings. Combining 3DVA with MD simulations is a generally applicable approach to generate testable hypotheses of how conformational changes in buried side chains might regulate function in enzymes.

12 August 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CGCarmen Gratteri
Carmen Gratteri
FAFrancesca Alessandra Ambrosio
Francesca Alessandra Ambrosio
Antonio LupiaAntonio Lupia
Antonio Lupia
FMFederica Moraca
Federica Moraca
BCBruno Catalanotti
Bruno Catalanotti
SAStefano Alcaro
Stefano Alcaro
(1) Background: SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) is a promising therapeutic target to fight COVID-19, and many RdRp inhibitors nucleotide/nucleoside analogs, such as remdesivir, have been identified or are in clinical studies. However, the appearance of resistant mutations could reduce their efficacy. In the present work, we structurally evaluated the impact of RdRp mutations found at baseline in 39 patients treated with remdesivir and associated with a different degree of antiviral response in vivo. (2) Methods: A refined bioinformatics approach was applied to assign SARS-CoV-2 clade and lineage, and to define RdRp mutational profiles. In line with such a method, the same mutations were built and analyzed by combining docking and thermodynamics evaluations with both molecular dynamics and representative pharmacophore models. (3) Results: Clinical studies revealed that patients bearing the most prevalent triple mutant P323L+671S+M899I, which was present in 41% of patients, or the more complex mutational profile P323L+G671S+L838I+D738Y+K91E, which was found with a prevalence of 2.6%, showed a delayed reduced response to remdesivir, as confirmed by the increase in SARS-CoV-2 viral load and by a reduced theoretical binding affinity versus RdRp (ΔGbindWT = −122.70 kcal/mol; ΔGbindP323L+671S+M899I = −84.78 kcal/mol; ΔGbindP323L+G671S+L838I+D738Y+K91E = −96.74 kcal/mol). Combined computational approaches helped to rationalize such clinical observations, offering a mechanistic understanding of the allosteric effects of mutants on the global motions of the viral RNA synthesis machine and in the changes of the interactions patterns of remdesivir during its binding.

5 March 2025 in Heliyon
Verified
Journal Article
Open access
Akash Deep BiswasAkash Deep Biswas
Akash Deep Biswas
EMANUELA SABATOEMANUELA SABATO
EMANUELA SABATO
SVSerena Vittorio
Serena Vittorio
PAParisa Aletayeb
Parisa Aletayeb
Alessandro PedrettiAlessandro Pedretti
Alessandro Pedretti
Giulio VistoliGiulio Vistoli
Giulio Vistoli